Get the Stockscreener App
58.15
1.63%
0.93
After Hours:
58.15
Exelixis Inc stock is traded at $58.15, with a volume of 1.86M.
It is up +1.63% in the last 24 hours and up +7.53% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$57.22
Open:
$57.65
24h Volume:
1.86M
Relative Volume:
0.74
Market Cap:
$14.41B
Revenue:
$2.38B
Net Income/Loss:
$833.42M
P/E Ratio:
19.27
EPS:
3.0172
Net Cash Flow:
$917.69M
1W Performance:
+2.20%
1M Performance:
+7.53%
6M Performance:
+40.90%
1Y Performance:
+46.92%
1-Day Range:
$57.33
$59.09
1-Week Range:
$56.33
$59.15
52-Week Range:
$33.76
$59.72
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
58.15 | 13.91B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis FDA Delay Moves Zanzalintinib Decision to March 2027 - TechStock²
Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value - webull.com
Form 8K Exelixis Inc For: 11 September By Investing.com - Investing.com Australia
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term - Stocktwits
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug - Investor's Business Daily
FDA extends review of Exelixis drug application for metastatic colorectal cancer - Investing.com Nigeria
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In - Benzinga
EXEL Looks 21.5% Overvalued on GF Value™ as PDUFA Delay Sparks Volatility - GuruFocus
FDA extends review of Exelixis’ colorectal cancer drug candidate - endpoints.news
US FDA extends review of Exelixis’ cancer drug - WSAU
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - ca.finance.yahoo.com
FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027 - AllSci
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months - Yahoo Finance
US FDA extends review of Exelixis' cancer drug - Reuters
Why is Exelixis stock sliding today? By Investing.com - Investing.com Canada
Exelixis stock falls as FDA extends zanzalintinib review By Investing.com - Investing.com South Africa
Exelixis stock falls as FDA extends zanzalintinib review - investing.com
EXEL Looks 24.3% Overvalued on GF Value™ - GuruFocus
Form 8K Exelixis Inc For: 11 September - Investing.com India
FDA Extends Review Timeline for Exelixis Cancer Drug - TipRanks
U.S. FDA extends review of Exelixis' cancer drug - Yahoo Finance
Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules - Yahoo Finance
La FDA américaine prolonge l'examen du médicament anticancéreux d'Exelixis - TradingView
Die US-amerikanische FDA verlängert die Prüfung des Krebsmedikaments von Exelixis - TradingView
Discipline and Rules-Based Execution in EXEL Response - Stock Traders Daily
Adagene earns milestone under Exelixis ADC collaboration - BioWorld News
Adagene Inc. Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - marketscreener.com
Adagene Receives Milestone Payment From Exelixis - marketscreener.com
Exelixis at Citigroup summit: building a second growth engine - Investing.com
Exelixis at Citigroup summit: building a second growth engine By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo! Finance Canada
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - Yahoo! Finance Canada
Transcript : Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11 - marketscreener.com
Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026) - JD Supra
Exelixis at Wells Fargo conference: zanzalintinib takes center stage By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Biotech with Robust Revenue Growth and Strategic Partnerships - DirectorsTalk Interviews
Exelixis Stock Price Forecast. Should You Buy EXEL? - StockInvest.us
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Exelixis stock hits all-time high at 57.68 USD By Investing.com - Investing.com Australia
EXEL - Finviz
Exelixis stock hits all-time high at 57.68 USD - investing.com
Exelixis (EXEL) Receives a Hold from BMO Capital - The Globe and Mail
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2026 - BioSpace
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
Exelixis secures Cabometyx exclusivity with patent win - BioWorld News
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data - Seeking Alpha
Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win - Law360
Exelixis wins appeals court ruling upholding key patents, FDA approval barred until at least Jan 15, 2030 - TradingView
Exelixis Wins Appeal in Patent Case Against MSN Laboratories - marketscreener.com
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win - GuruFocus
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):